Strategies on Control of MDRO in Europe

Herman Goossens Vaccine & Infectious Disease Institute University of Antwerp Belgium Chair of the Technical Advisory Committee of the EAAD ECDC, Stockholm Sweden

VÐ.

Outline



- Problems of antibiotic (ab)use and resistance in Europe
- Towards a European antibiotic policy
 - First steps
 - Member States initiatives
- National and European campaigns
 - On prudent antibiotic use
 - On hand hygiene in hospitals
- Towards a Global policy
 - Transatlantic Task Force for Antimicrobial Resistance (TATFAR)
 - World Health Day, April 7th 2011







"If you cannot measure it, you cannot improve it"

Lord Kelvin, 1824-1907



ESAC: European Surveillance of Antimicrobial Consumption

 Launched in November 2001 (Belgian EU Presidency)



- ESAC is an international network of surveillance systems, aiming to maintain a continuous, comprehensive and comparable database on antimicrobial consumption for all Member States candidate countries and EFTA-EEA countries
- Coordinator: Herman Goossens (UA)

- Funding organisation: DG SANCO of EC (2001-2007) and ECDC (2007-2011)
- Transfer to ECDC (Stockholm) in July 2011

VP Total outpatient antibiotic use in DID in 31 European countries in 2009



* Total care : LT, CY * MT : 2008 data Source: ESAC

No statistical Differences in Recovery between those Prescribed Antibiotics and Those Not Prescribed Antibiotics CA-LRTI (survival analysis)



Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe



Correlation Between Penicillin Use and Prevalence of Penicillinresistant *S. pneumoniae*



Consumption of Penicillin (J01C) in DID, AC 2000

| Organism year of isolation <i>[source of information]</i> | Antibiotic resistance | Antibiotic use - ATC group (year of data) | No. of countrie s | Spearman correlation (r) (confidence interval) | <i>P</i> -value |
|--|--------------------------|---|-------------------------|---|-----------------|
| S. pneumoniae 2001 [7] | Penicillin | Penicillin – J01C (2000) | 19 | 0.84 (0.62-0.94) | <0.001 |

Goossens et al., Lancet 2005; 365: 579-87



- Mean pre-antibiotic (Day 0) carriage of macrolide-resistant streptococci was 28%
- Use of both macrolides resulted in a huge increase in resistant streptococci, which persisted for at least 6 months ($P \le 0.01$)
- In the azithromycin group, resistance remained at a higher level than in the clarithromycin group during mid-time points (P≤0.001)





The symbols \uparrow and \checkmark indicate a significant increasing or decreasing trend for the period 2006-2008

-

Source: EARS-Net 2010

K.pneumoniae: Proportion of Invasive Cephalo-3 Resistant Isolates, 2009



The symbols \uparrow and \checkmark indicate a significant increasing or decreasing trend for the period 2006-2008

Source: EARS-Net 2010

K.pneumoniae: Proportion of Invasive Carbapenem Resistant Isolates, 2009



Source: EARS-Net 2010

Were an and a set of NDM-1 Producing *Enterobacteriaceae* in Europe

- ECDC conducted a questionnaire survey in all EU Member States, Iceland and Norway
- By 4 October 2010, a total of 77 cases were reported from 13 countries in 2008-2010











Lepape A & Monnet DL, Euro Surveill, November 2009





Hospital number

Ver Prevalence of AM Use by Hospital



Ver Society's Failure

- Antibiotic sales in the community represent > 90 % of all antibiotic use and is, therefore, an important component in the selection pressure
- The largest use of these antibiotics is towards minor respiratory tract infections which are often selflimiting and self-healing and for which AB real usefulness is dubious
 - pharyngitis
 - bronchitis
 - flu-like syndrome, ...
- Antibiotic use will select for antibiotic resistance

VÐ.

Outline



- Problems of antibiotic (ab)use and resistance in Europe
- Towards a European antibiotic policy
 - First steps
 - Member States initiatives
- National and European campaigns
 - On prudent antibiotic use
 - On hand hygiene in hospitals
- Towards a Global policy
 - Transatlantic Task Force for Antimicrobial Resistance (TATFAR)
 - World Health Day, April 7th 2011



First Steps Towards a European Antibiotic Policy



- July 1998: "Opinion of the Economic & Social Committee on Resistance to Antibiotics as a Threat to Public Health"
- September 1998: EU Conference on the Microbial Threat, Copenhagen & "Copenhagen Recommendations" <u>http://www.im.dk/publikatio</u> <u>ner/micro98/index.htm</u>
- May 1999: "Opinion of the Scientific Steering Committee on Antimicrobial Resistance"





Council Recommendations on the prudent use of antimicrobial agents (2001), and on healthcare associated infections (2009)



| 53.1992 DE Official (second of the B | aropean Constantiller L 34(03 | | 3.7.2009 EN Official Journa | al of the Etitopean Union C 15 |
|---|---|--|--|--|
| | | | | 1 |
| | | | (Revolutione, rec | orwardations and opinions) |
| çeze whee pelilonis | n is ne olfgerøyi | | | |
| | | | PECON | MENDATIONS |
| COUL | NCIL | | RECOMMENDATIONS | |
| | | | C | DUNCII. |
| COUNCIL BLOOD | ADD NO. TON | | | |
| of 15 Nava on the product use of antimics | nder 2001 Bid agents in hannen medicine | | COUNCIL | RECOMMENDATION |
| (Jun with H | a elevaniej | | م المالية الم | 9 June 2009 |
| (2042)7 | 7)80 | | on patient satery, including the prevent | on and control of leasticare azociated intections 09/C 151/01) |
| THE COUNCE OF THE EXCORACY UNION | highlights that antisticabilit maintance increases mathling and materiality day to compare table discourse | | THE COUNCIL OF THE EUROPEAN UNION, | EU, and that 37 000 deaths are caused every year a |
| Rotag reged to the Street workliding the European Community, and in particular Article 15/24 thereof, | and leads not only to a diministion of quality of life but size to additional health and modual care cores, and that acting meets to be taken at Community level. | | Having regard to the Treaty establishing the Europe Committing, and in particular the second subparagraph Autob 15700 income | result of such infections. of |
| Rating regard to the proposal from the Commission, | 14 The convictingly opinion of the figurousic and focul | | Maving regard to the proposal from the Commission, | (4) Poor patient safety represents both a servere public her problem and a high economic burden on limited her resources. A large proportion of adverse wrents, both the hospital sector and in primary care, are provents |
| Whener | Committee on the Resistance to antibiotics as a depart to police hadds (7) identified possible initiative and attion that should be taken as Marcher Sono and Community that should be taken as Marcher Sono and Community | | Maving regard to the opinion of the European Parliament (| with systemic factors appearing to account for a majo of them. |
| | and a same or provide a second record. | | Social Committee (?), | This assume data with user and assume to a supervision of the second seco |
| (i) deteniordeial agents are substances produced other synthetically or notarilly by hotteria, hangi or planta, used to full or inhibit the growth of micro-superisons including hotterial systems and hand and of securities in | (9) These is an association between the persiding use of antimizer-bid opens and an instance in the persidence of | | Maving regard to the opinion of the Committee of the Regions (1). | work on patient safety carried out by the World He Organization (WHO) shough in: World Allance Patient Safety, the Council of Europe and the Organization (WHO) |
| pertitulie precise. | many-segaritoric restant to those again, but the ela- tionship is closely not a simple use. These are many possible for the formation the data set of the balance | | Wharear | tation for Economic Cooperation and Developm (OECD). |
| (2) The new of antimicrobial agents has granify contributed to improvements in health. Such invariantly agent have been tracked in a device to track and second them. | these related to the organizer, to the bose and to the made of our of such drug. However, it is clear that antisticabilit redences may not recovered by we- | | (1) Article 152 of the Treaty provides that Communi- action, which shall complement national policies, shi be directed covards improving giblic health, powersi- himan fibres and disease, and eliminating coincer. | ty all % (4) The Community, through the seventh framework of an anti-community of an anti-community of anti- |
| infactions diseases and infactions. However, their use has been as comparing by an increasing prevalence of infact- ergenisms that have availed residence to one or more | ner attaccolal corporate. | | danger to himan hasht. | research in health systems, in particular in the quar- of healthcare provision under the Health The inductions of prior on primer softw. The later is |
| of these seconded testimizedial existence". Secondaria- bial resistance poses a threat to policy heads, may | in To device remain the provention of infections and | | 12 % of patients admitted to hospital staffer from adver events whilst receiving healthcare (%). | 20 given particular attention under the Information Communication Technology Theme. |
| const and has moreover implemented for sensing. There fore compared action is presently at Compared by level to | entries anothing wild, while not compariso dra- | | (3) The European Centre for Disease Prevention and Control | al |
| comain this problem by encouraging the product use of antinazofied approx in feature modifier and better hypitas and it forther control. | mentant mice-regarisms as well as on pre-express and use of architectrial agents must be conflicted throughout the Community Three dendd from an exer- | | azzodated infectiona occur in one hospitalised patie in 20, that is to say 4,1 million patients a year in d | (7) The Commission, in its White Paper Together for He A Strategic Approach for the EU 2008-2017 23 October 2007, identifies patient safety as an |
| m. The descel of the forecast links as it includes | tial component for an overall surveillance energy to address the problem of estimatedial medianose and in manufacture and the surveillable formers of the | | Opinion of 23 April 2009 (not yet published in the Official Journ) Opinion of 25 March 2009 (not yet published in the Offic | tor action. |
| p) the control of the barrypoil (2000 of 4 June 1999) adapted a Resolution on antibiotic resistance partial A starting against the mitrobial threat/§. The Resolution | percourt, to many the point of the bound of the set of antimizerbid agrees and the development of resistance among these pathogens. | | journal). (*) Opinion of 22 April 2007 (not yet published in the Official Journ (*) Teichnical report Improving Patient Safety in the SUP proper for the European Committion, published 2000 by the EAN | (r) Lecase No 1953/2064/EC at the Lungean Tarlament and a d). Council of 18 December 2006 concerning the sewarth frame or programme of the Lungean Contraunity for research, inclinate D development and demonstration activities (2007-2013) (O) L. |
| H RECORDERATION P. L | P(0) C 407, 2012 (1990, p. 7. | | Cooperation. | sourcement, p. 11- |
| | | | | |
| | | | | |

Council Recommendation of 15 November 2001 on the prudent use of antimicrobial agents in human medicine (2002/77/EC) Council Recommendation of 9 June 2009 on patient safety, including the prevention and control of healthcare associated infections (2009/C 151/01)



Country Visits Organised by ECDC to Discuss Implementation of Council Recommendations, 2006-2011







Country visits to discuss AMR issues (as of February 2011)

- Based on Council Recommendation of 15 November 2001 on the prudent use of antimicrobial agents in human medicine (2002/77/EC)
- Reports (observations, conclusions, suggestions, examples of best practice
- 14 initial visits (see map)
- 5 follow-up visits (Czech Rep., Greece
- x 2 and Hungary x 2)
- 5 visits budgeted for 2011

VÐ.

Outline



- Problems of antibiotic (ab)use and resistance in Europe
- Towards a European antibiotic policy
 - First steps
 - Member States initiatives
- National and European campaigns
 - On prudent antibiotic use
 - On hand hygiene in hospitals
- Towards a Global policy
 - Transatlantic Task Force for Antimicrobial Resistance (TATFAR)
 - World Health Day, April 7th 2011

Were Belgian National Public Campaigns



- Organised by: BAPCOC (Belgian Antibiotic Policy Coordination Committee)
- Budget:
 - 400,000 EUR/annual campaign
- Interventions targeting the public:
 - Ads on TV, radio and newspaper
 - Information booklets
 - Folders
 - Posters
 - Internet campaigns: www.antibiotics-info.be



BAPCOC Organised Three Different Awareness Campaigns

2000 - 2003 (3 winters)

2004 - 2008 (4 winters)





2008 - ... (launched 18.11.08)



OPGELET VOOR DE NEVENWERKINGEN

Als je antibiotica gebruikt, kunnen er ook bijwerkingen optreden. Antibiotica vallen namelijk niet alleen de schadelijke bac-teriën aan. Ook de nuttige moeten eraan geloven. Raadpleeg je arts indien je klachten blijven duren.

Allergische reacties

Een allergische reactie op antibiotica kan jeuk of huiduitslag veroorzaken. Gelukkig komen emstige gevallen zelden voor. Diarree

Antibiotica kunnen het normale evenwicht verstoren in je darmen. Met diarree als gevolg.

Maaglast

Tijdens de behandeling met antibiotica kan je last hebben van een zwaar gevoel in de maag. Mogelijk verlies je ook je eetlust of is ie smaakzin verstoord.

Schimmelinfecties

Een behandeling met antibiotica verhoogt ook de kans op schimmelinfecties van huid en slijmvliezen. Met witverlies bij vrouwen of wit beslag in de mond als gevolg.

Risicogroepen

Sommige mensen moeten extra voorzichtig zijn wanneer ze antibiotica nemen. Denk maar aan zwangere wouwen of vrouwen die borstvoeding geven. Ook mensen met een nierziekte of een leverziekte moeten extra opletten. Behoor je tot deze risicogroepen, meld het dan beslist aan je arts.

PRAAT EROVER MET **JE ARTS OF A POTHEKER.**

Als je ziek bent, vraag je advies aan je arts of apothe ker. Niet meer dan correct. Maar in deze folder lees je dat antibiotica niet altijd de correcte oplossing zijn bij winterkwalen. Stel je daarom beslist deze vragen bij je doktersbezoek

• Wat schrijft mijn arts voor? Zijn het antibiotica? Gaan antibiotica effect hebben op mijn klachten? Welke dosissen en tijdstippen moet ik respecteren

Coördinatie en wetenschappelijk ondersteuning Belgische Commissie voor de Coördinatie van het Antibioticabeleid | bapcoc@health.fgowbe

Een initiatief van de Federale Overheidsdienst Volksgezondheid, Veiligheid van de Voedse keten en Leefmilieu Met desteun van het RIZIV

Antibiotica in Cardenauter BAPCOC

OPGELET: ALLEEN GEBRUIKEN INDIEN NODIG. ANTIBIOTICA HEBBEN GEEN ZIN BU GRIEP, BRONCHITIS OF EEN VERKOUDHEID.

EN WAT DAN WEL?

BAAT HET NIET, DAN SCHAADT HET WEL

Tild geneest

Antibiotica zijn een mooie uitvinding. Tenminste: als ze correct gebruikt worden. Zo helpen ze niet bij griep, verkoudheid, acute bronchitis en de meeste vormen van keel- en oprontsteking. Deze infecties worden veroorzaakt door virussen en/ of we genezen er spontaan van na enkele dagen. Hiervoor antibiotica gebruiken, heeft everweel zin als de hele dag met zwembandjes rondlopen.

Wanneer zijn antibiotica dan wel nodig?

Antibiotica zijn enkel nodig als we emstig ziek zijn door bacteriân. Bacterián zijn minuscuul kleine levende wezens die zich zeer snel kunnen vermenigvuldigen. Niet alle bacteriën zijn schadelijk voor de mens; sommige zijn zelfs nuttig. Bacteriën kunnen echter ook onder andere longontsteking, hersenvlies-ontsteking, wondinfecties en enkele ernstige vormen van keelen oprontsteking veroorzaken. Dan is een behandeling met antibiotica nodig om ons afweersysteem te helpen deze schadelijke bacteriën te vernietigen.



Hebben kinderen vaker antibiotica nodig dan volwassenen?

Ja en neen. Kinderen zijn veker ziek, dus ook wat veker ernstig ziek. Maar ook bij kinderen helpen antibiotica niet bij griep, varianischeid prute branchitis an de meeste vorman von keel. en oprontsteking. Bovendien ontheem je kinderen de kans om hun eigen afweersysteem op te bouwen en aan te scherpen door onnodig antibiotica te geven.

ANTIBIOTICA OF NIET?

Je arts is de geschikte persoon om de juiste behandeling in te stellen. Soms moet eerst een bloedstaal of uitstrijkje van de keel onderzocht worden

Antibiotica doen niets aan virale infecties en hebben nauwelijks effect op gewone bacteriële infecties. Deze genezen sportaan. De symptomen kunnen wel bestreden worden zodat de zieke zich beter voelt. Bij emstige infecties veroorzaakt door bacteriën is een behandeling met antibiotica wel noodzakelijk.

| IIEKT | GENERSMIDDELEN | AANBEVELINGEN | |
|---|---|--|--|
| Griep | Pijntillen, koorts- werende midden | Rust, vaccinatie ter preventie | |
| Sinusta | Pijnstillers, koorts- werende middelen | Stomen mat warm water | |
| Clames | Somt entidiarres- mbblelen | Valdzende drinken, goede tygeine | |
| Verkoudheid | Pipittilen | Tabak vermijden | |
| Azute broaditte | Pijntilan | Tabal vernijden | |
| Keelontsteking | Pijntillen. | Tabak vermijden | |
| Dorontariaking | Pijnstillers, koorts- werende middelen | Rust | |
| Longostatelling | Antibiotica | Ernstig, goad op te volgen door arbi, ionis opname in ziekenhuis | |
| Bacteriële henervlies- setsteling | Antibiotica | Ernetig, good op te vol- gen door arts, opname in stekenhuis | |

BELANGRUK: GEBRUIK ANTIBIOTICA ALTIJD CORRECT

OPGELET:

ANTIBIOTICA HEBBEN GEEN ZIN BL

INDIEN NODIG.

ALLEEN GEBRUIKEN

Als je arts antibiotica voorschrijft, is het belangrijk dat je de voorgeschreven behandeling nauwkeurig volgt. Alleen zo ben je zeker dat alle bacteriën vernietigd zullen worden en vermijd ie de selectie van resistente bacteriën /zie resistentie).

Vuistregels

Respecteer de dosissen en de tijdstippen. Sla nooit een inname over en gebruik de voorgeschreven hnoveolhoden.

Stop niet woeger dan voorgeschreven. Maak je antibioticakuur volledig af. Ook als je je na een paar dagen al beter voelt. Dat is nodig omdat de bacteriën slechts geleidelijk worden vemietigd.

Bewaar ze niet. Hou nooit restjes antibiotica bij voor een volgende keer. Breng ze naar je apotheker.

WAT IS RESISTENTIE?

Door het niet correct gebruik van antibiotica, neemt het aandeel toe van bacteriën die weerstand kunnen bisdan tegen antibiotica. Deze bacterien zijn met an-dere woordan resistent of ongevoelig voor antibiotica. Zokunnen emstige ziektes niet meer even vict en doel-ter fland behandeld worden als voorheen. Ook heelkundige ingrepen van wondzorg tot transplantaties worden risicovol als antibiotica niet meer werken.

OPGELET: ALLEEN GEBRUIKEN INDIEN NODIG.

BEN GEEN ZIN BIJ GRIEP, BRONCHITIS OF EEN VERKOUDHEID

PRAAT EROVER MET JE ARTS OF APOTHEKER

R INFO OP WWW.GEBRUIKANTIBIOTICACORRECT.BE

we entity the tip door locards, this of argumenting, tensors around any wrond-acted to ensure entity. αξι λατικόσει παραγικατι στι αναφαγηρισμού οπί όμαν απόσαμα αυταπτικι το κατακοιχία. Απορισται παιρέα τακτός bit en de meets wirnee fan Lee- ee potostigenij, dwe ie worde worden wirderige dat wirneer wird we generet et I gestrumen mehr erseinen sin zu die erse sig mit swertes biges konstigen.

AD INCIDENT OF REMAIN REPORTED AND PROVIDED AND REMAINING A PERSON OF A PERSON



OPGELET: ALLEEN GEBRUIKEN INDIEN NODIG

Gebruik antibiotica ook alleen als het nodig is

www.gebruikantibiolicacorrect.be





Belgian Campaigns 2002-2010 Outpatient antibiotic use in Belgium in packages per 1,000 inhabitants per day – July - June



We Belgian Campaigns 2002-2007 Outpatient antibiotic Use in Belgium in EUR, January - December



Antibiotic Resistance of *S. pneumoniae* in Belgium 1985 - 2009

Vi



\$

VP French Awareness Campaigns

- When: since November 2002, annually during winter season
- Organised by: French Social Insurance System
- Budget:
 - 4 million EUR/annual campaign
- Interventions targeting the public:
 - Ads on TV, radio and newspaper
 - Information leaflets
 - Folders
 - Travelling exhibition around France
 - Internet campaigns:

www.antibiotiquespasautomatiques.com

Very French Campaigns 2002-2007 Outpatient antibiotic use in France in prescriptions per inhabitant – October to March



Sabuncu et al., PloS Medicine; June 2009



Antibiotic Use by Age Group in France



% Variation /année (N-1)



http://www.ameli.fr/fileadmin/user_upload/documents/DP_Antibiotiques_10-01-2008.pdf



Conclusions



- National public campaigns have been very successful to reduce antibiotic use and resistance in Belgium and France
- Huge cost savings: for 1 € invested, about 8 were saved
 - Belgium: 250 million EUR 2000-2010
 - France: 845 million EUR 2002-2010
- Decrease of antibiotic use amplified by the effect of the 7 valent conjugated pneumococcal vaccine
- In both countries actions were also directed towards the prescribers:
 - academic detailing
 - distribution of guidelines
 - individual feed-back of antibiotic prescriptions
 - promotion of streptococcal antigen tests (only France)

The burden of antibiotic resistance warrants a multifaceted approach

18 November 2008 **EUROPEAN** ANTIBIOTIC AWARENESS DAY

A European Health Initiative







- Establishment of Technical Advisory Committee (national experts, Commission, WHO EURO, CPME, ESCMID)
- Focus on awareness raising amongst general public about not using antibiotics when not necessary, e.g. for colds and flu
- Based on successful national campaigns (Belgium and France)



Slogans & logos





A European Health Initiative 🧾







A European Health Initiative



Vertice Matter Vertice Antibiotics



Images from National Campaigns: Belgium, Cyprus, Poland, England, Luxembourg, Greece







EAAD, 2008-2011

COLD? FLU? TAKE CARE

NOT ANTIBIOTIC

A European Health Initiative

2008

Materials for general public 32 countries participated

2009

- Article in Eurosurveillance
- Materials for primary care prescribers
- Website translated in all EU languages, three TV spots developed
- 34 countries participated

2010

- 36 countries participated
- Materials for hospital prescribers
- Matched Get Smart week in the United States and the campaign in Canada





EAAD 2010 Media coverage



| Key Figures | | | | |
|---|--|--|--|--|
| • Number of clippings | 476 | | | |
| Reach (print) Circulation (print) Visits (online) | 51,334,208 17,152,770 54,241,600 | | | |









Special Eurobarometer 338 / 72.5 "Antimicrobial resistance", Nov.-Dec. 2009.



Why is the EAAD so successful ?



- Strong upfront political support and commitment at European and national level;
- Planning well ahead;
- Building on existing success stories of countries;
- Early establishment of a Technical Advisory Committee with dedicated experts;
- Briefing of national communications contact points prior to the campaign and sharing contact information;
- Initiation of a broad stakeholder contact programme to inform interest groups and invite contributions;
- Good support from professional organisations,
- Development of campaign key messages and visuals with the support of experts in social marketing.



FIRST GLOBAL PATIENT SAFETY CHALLENGE



To reduce health care-associated infections Hand hygiene as the cornerstone







"Vous êtes en de bonnes mains"

Hygiène des mains

Quand ?

Les 5 indications





Avant tout contact direct avec un patient Un contact social court (par ex. serrer la main) est probablement associé à un risque de transmission moindre

APRES exposition aux liquides biologiques



Après un acte comportant un risque d'exposition à des liquides biologiques qui normalement s'anticipe par le port de gants

En cas d'exposition accidentelle à des liquides biologiques ou des muqueuses, lavage des mains suivi d'une friction à la solution hydro-alcoolique



En quittant un patient après un ou des contacts directs

APRES contact avec l'environnement du patient



Après avoir touché des objets ou des surfaces à proximité immédiate du patient

L'environnement peut avoir été contaminé par le patient ou lors d'un soin précédent

AVANT acte propre/invasif



Immédiatement avant un soin propre Immédiatement avant un geste invasif

Port de gants si risque d'exposition à des liquides biologiques ou des muqueuses

En cas de souillures visibles, se laver les mains, les sécher puis les désinfecter avec la solution hydro-alcoolique



"Vous êtes en de bonnes main



Methodology



Nation-wide campaign:

- **2004:** preparation of first campaign by working group of federal platform of hospital hygiene with the financial support of the ministry of Health
- Objective: Raising awareness on good hand hygiene practices and promote use of alcohol handrubs
- Target population:
 - **HCW** having contact with patients in hospitals
 - And hospitalised patients
 - In acute, chronic and psychiatric hospitals



Methodology: Two components



- Awareness campaign with standardised material to improve Hand Hygiene compliance distributed to participating institutions
- 2. Measuring impact of the campaign
 - Hand Hygiene compliance (soap and/or alcohol / Hand Hygiene opportunities)
 - Alcohol rub consumption (liters alcohol rub / 10,000 patient days)
 - Respect of basic hygiene conditions (optional, only 3rd campaign)

VP Planning of Campaigns



Ver Awareness Campaigns: UP Multi Modal

- Reminders (posters) in accordance with the WHO guidelines
- Education of Healthcare workers
 - Standardised powerpoint presentation
 - Interactive quiz
- Distribution of gadgets for Healthcare workers or patients
- Promotion of hand rub (posters, black light)
- Implication of patients (leaflets, gadget)
- Feedback of measurement results before and after campaign



Campaign Messages and Targets Varied!

• First campaign:

>Hand hygiene, just do it ... and with alcohol rubs

Second campaign:

>Hand hygiene, do it correctly

• Third campaign:

Do not wear jewellery or artificial nails and keep your nails clean

➤Use gloves correctly

Fourth campaign:

Patient empowerment: "Did you disinfect your hands" to increase the compliance before patient contact and to try to exceed the 70% compliance after campaign

Verage Hand Hygiene Compliance



MRSA in Belgian acute care hospitals: proportion of *S.aureus* clinical isolates and incidence of nosocomial acquisition

1994 - 2009



Vor Conclusion: Campaigns Were Successful

- High participation rate
- Increase of Hand Hygiene compliance at short and long term
- Alcohol rub widely used
- → Key factors for success:
 - Multi modal awareness campaign
 - Repetition of campaign
 - National implication
 - Political and financial support

Counts of MRSA Bacteraemia Oct 2005 to June 2009



A. Pearson and colleagues (HPA, Sept 2009)



Estimated average procurement of Alcohol Hand Rub and Liquid Soap in mls per bed-day July 2004-December 2007 in 148 acute NHS Trusts



- 3-fold increase in combined use to 60 mls per pt-day
- Analysis shows highly significant association between each ml of AHR used and 1% drop fall in MRSA BSI

Stone S et al. ECCMID 2009 (abstract O140)

We MRSA and incidence per 100 admissions or 1000 days of hospitalisation. Univ. hospitals of Paris (n=39) 1993-2007



V. Jarlier, D. Trystram 2008





MRSA Bacteraemia Trends in Europe, 2007



Country code (average number of isolates reported per year) & year of start surveillance#

Courtesy: Grundmann et al. (EARSS)

VP Expert-Proposed European Strategies to Monitor and control Infection, Antibiotic Use and Resistance in Health-care Facilities

- Initiate or continue hand hygiene campaigns and use hand hygiene as a quality indicator
- Collection and monitoring of structure-of-care quality indicators and indicators of good practice (e.g. consumption of alcohol solution)
- ECDC Point Prevalence Surveys on HAI and AB Use (completed in all Member States by November 2012; repeated at least once every 5 years)
- National LTCF resident safety programmes, external audits of LTCF and monitoring

Goossens, Lancet Infect Dis 2011, April 7th

VÐ.

Outline



- Problems of antibiotic (ab)use and resistance in Europe
- Towards a European antibiotic policy
 - First steps
 - Member States initiatives
- National and European campaigns
 - On prudent antibiotic use
 - On hand hygiene in hospitals
- Towards a Global policy
 - Transatlantic Task Force for Antimicrobial Resistance (TATFAR)
 - World Health Day, April 7th 2011

VP Trans Atlantic Task Force on Antimicrobial Resistance - TATFAR EU-US Summit Declaration – Washington

3 November 2009



The EU-US Summit Declaration called for the establishment of "...a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us".



Organisations - US



United States Department of Health and Human Services:



Office of Global Health Affairs (OGHA)



Centers for Disease Control and Prevention (CDC)



Food and Drug Administration (FDA)



National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID/NIH)

Organisations - EU





European Commission:

EC-Directorate General for Health and Consumers EC-Directorate General for Research European Centre for Disease Prevention and Control (ECD European Medicines Agency (EMA) European Food Safety Authority (EFSA)

Council of the European Union: Represented by the TRIO Presidency (Spain, Belgium, Hungary)

trio.be



VP TATFAR Outcome and Timeline



The expected outcome of the TATFAR is a review of ongoing and planned activities and a proposal with suggestions for areas of future collaboration between the EU and the US.

| September Launch of EU interaction third parties based on Commission website consultation | | <u>December</u> Interim draft reports from working groups (including input from public consultations) | | <u>31 March</u> Final report | |
|---|--|---|---|---------------------------------|---------------------------------|
| 2 | 010 | | 2011 | | |
| <u>June</u> TATFAR face to face meeting, US | <u>October -</u> <u>November</u> U.S. stakeholo meeting | ler | <u>January</u> Final draft reports from working groups | Marc Face | <u>h</u> to face meeting, EU |

VPAnd Now....UWorld Health Day, 7 April, 2011

COMBAT DRUG RESISTANCE

No action today, no cure tomorrow



Conclusion



"We have watched too passively as the treasury of drugs that has served us well has been stripped of its value. We urge our colleagues worldwide to take responsibility for the protection of this precious resource. There is no longer time for silence and complacency".

Carlet J, Collignon P, Goldman D, Goossens H, Gyssens I, Harbarth S, Jarlier V, Levy S, N'Doye B, Pittet D, Richtmann R, Seto W, van der Meer J and Voss A. Lancet, 2011; April 7th



Acknowledgement



Anne Simon and many other colleagues of the Belgian Antibiotic Policy Coordination Committee (BAPCOC)

- Belgian Chief Medical Officer, Christiaan Decoster
- Belgian Ministers of Public Health (Frank Vandenbroucke, Magda Aelvoet, Rudy Demotte and Laurette Onkelinx
- Dominique Monnet and Sarah Earnshaw of ECDC, Stockholm